Australia's CSL rises as company launches trials for patented manufacturing process

CSL

29/07/2026 02:19

Updates
** Shares of biotechnology major CSL CSL.AX rise 5.6% to A$126.59, their highest point since July 9
** Stock on track for its best day since June 19, if gains hold
** Company says it will undertake clinical trials to support the regulatory approval process of Horizon 2, a patented manufacturing process 
** Horizon 2 is designed to boost immunoglobulin production from the same amount of plasma
** Citi says need for clinical studies likely extends Horizon 2 approval timeline, with meaningful earnings benefits unlikely before 2030
** Stock down 26.9%, YTD 

 (Reporting by Jasmeen Ara Shaikh & Rajasik Mukherjee in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))